These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 10193713

  • 1. Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure.
    Havranek EP, Thomas I, Smith WB, Ponce GA, Bilsker M, Munger MA, Wolf RA.
    J Am Coll Cardiol; 1999 Apr; 33(5):1174-81. PubMed ID: 10193713
    [Abstract] [Full Text] [Related]

  • 2. Renal response to the angiotensin II receptor subtype 1 antagonist irbesartan versus enalapril in hypertensive patients.
    Pechère-Bertschi A, Nussberger J, Decosterd L, Armagnac C, Sissmann J, Bouroudian M, Brunner HR, Burnier M.
    J Hypertens; 1998 Mar; 16(3):385-93. PubMed ID: 9557932
    [Abstract] [Full Text] [Related]

  • 3. A study of the efficacy and safety of irbesartan in combination with conventional therapy, including ACE inhibitors, in heart failure. Irbesartan Heart Failure Group.
    Tonkon M, Awan N, Niazi I, Hanley P, Baruch L, Wolf RA, Block AJ.
    Int J Clin Pract; 2000 Mar; 54(1):11-4, 16-8. PubMed ID: 10750252
    [Abstract] [Full Text] [Related]

  • 4. ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects.
    Murdoch DR, McDonagh TA, Farmer R, Morton JJ, McMurray JJ, Dargie HJ.
    Am Heart J; 2001 May; 141(5):800-7. PubMed ID: 11320369
    [Abstract] [Full Text] [Related]

  • 5. Acute and 3-month treatment effects of candesartan cilexetil on hemodynamics, neurohormones, and clinical symptoms in patients with congestive heart failure.
    Mitrovic V, Willenbrock R, Miric M, Seferovic P, Spinar J, Dabrowski M, Kiowski W, Marks DS, Alegria E, Dukát A, Lenz K, Arens HA.
    Am Heart J; 2003 Mar; 145(3):E14. PubMed ID: 12660683
    [Abstract] [Full Text] [Related]

  • 6. Effects of long-term angiotensin II AT1 receptor blockade on survival, hemodynamics and cardiac remodeling in chronic heart failure in rats.
    Richer C, Fornes P, Cazaubon C, Domergue V, Nisato D, Giudicelli JF.
    Cardiovasc Res; 1999 Jan; 41(1):100-8. PubMed ID: 10325957
    [Abstract] [Full Text] [Related]

  • 7. Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group.
    Crozier I, Ikram H, Awan N, Cleland J, Stephen N, Dickstein K, Frey M, Young J, Klinger G, Makris L.
    Circulation; 1995 Feb 01; 91(3):691-7. PubMed ID: 7828295
    [Abstract] [Full Text] [Related]

  • 8. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension.
    Pool JL, Guthrie RM, Littlejohn TW, Raskin P, Shephard AM, Weber MA, Weir MR, Wilson TW, Wright J, Kassler-Taub KB, Reeves RA.
    Am J Hypertens; 1998 Apr 01; 11(4 Pt 1):462-70. PubMed ID: 9607385
    [Abstract] [Full Text] [Related]

  • 9. The pharmacokinetics and pharmacodynamics of irbesartan in heart failure.
    Kostis JB, Vachharajani NN, Hadjilambris OW, Kollia GD, Palmisano M, Marino MR.
    J Clin Pharmacol; 2001 Sep 01; 41(9):935-42. PubMed ID: 11549097
    [Abstract] [Full Text] [Related]

  • 10. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group.
    Baruch L, Anand I, Cohen IS, Ziesche S, Judd D, Cohn JN.
    Circulation; 1999 May 25; 99(20):2658-64. PubMed ID: 10338459
    [Abstract] [Full Text] [Related]

  • 11. Effects of angiotensin-converting enzyme inhibitor plus irbesartan on maximal and submaximal exercise capacity and neurohumoral activation in patients with congestive heart failure.
    Blanchet M, Sheppard R, Racine N, Ducharme A, Curnier D, Tardif JC, Sirois P, Lamoureux MC, De Champlain J, White M.
    Am Heart J; 2005 May 25; 149(5):938.e1-7. PubMed ID: 15894946
    [Abstract] [Full Text] [Related]

  • 12. Comparison of the effects of AT1 receptor blockade and angiotensin converting enzyme inhibition on atherosclerosis.
    Hope S, Brecher P, Chobanian AV.
    Am J Hypertens; 1999 Jan 25; 12(1 Pt 1):28-34. PubMed ID: 10075381
    [Abstract] [Full Text] [Related]

  • 13. Comparison of irbesartan with captopril effects on cardiac hypertrophy and gene expression in heart failure-prone male SHHF/Mcc-fa(cp) rats.
    Carraway JW, Park S, McCune SA, Holycross BJ, Radin MJ.
    J Cardiovasc Pharmacol; 1999 Mar 25; 33(3):451-60. PubMed ID: 10069682
    [Abstract] [Full Text] [Related]

  • 14. Clinical overview of irbesartan: expanding the therapeutic window in hypertension.
    Man in't Veld AJ.
    J Hypertens Suppl; 1997 Dec 25; 15(7):S27-33. PubMed ID: 9532518
    [Abstract] [Full Text] [Related]

  • 15. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators.
    Kassler-Taub K, Littlejohn T, Elliott W, Ruddy T, Adler E.
    Am J Hypertens; 1998 Apr 25; 11(4 Pt 1):445-53. PubMed ID: 9607383
    [Abstract] [Full Text] [Related]

  • 16. Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors.
    Granger CB, Ertl G, Kuch J, Maggioni AP, McMurray J, Rouleau JL, Stevenson LW, Swedberg K, Young J, Yusuf S, Califf RM, Bart BA, Held P, Michelson EL, Sellers MA, Ohlin G, Sparapani R, Pfeffer MA.
    Am Heart J; 2000 Apr 25; 139(4):609-17. PubMed ID: 10740141
    [Abstract] [Full Text] [Related]

  • 17. Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with heart failure.
    Dickstein K, Gottlieb S, Fleck E, Kostis J, Levine B, DeKock M, LeJemtel T.
    J Hypertens Suppl; 1994 Jul 25; 12(2):S31-5. PubMed ID: 7965263
    [Abstract] [Full Text] [Related]

  • 18. The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin.
    Perico N, Remuzzi A, Sangalli F, Azzollini N, Mister M, Ruggenenti P, Remuzzi G.
    J Am Soc Nephrol; 1998 Dec 25; 9(12):2308-17. PubMed ID: 9848785
    [Abstract] [Full Text] [Related]

  • 19. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Symptom, Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart Failure (STRETCH) Investigators.
    Riegger GA, Bouzo H, Petr P, Münz J, Spacek R, Pethig H, von Behren V, George M, Arens H.
    Circulation; 1999 Nov 30; 100(22):2224-30. PubMed ID: 10577995
    [Abstract] [Full Text] [Related]

  • 20. Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study.
    Palatini P, Jung W, Shlyakhto E, Botha J, Bush C, Keefe DL.
    J Hum Hypertens; 2010 Feb 30; 24(2):93-103. PubMed ID: 19458624
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.